NORTH Dakota | Health & Human Services
Be Legendary.

HEALTH ALERT NETWORK | HEALTH ADVISORY | JANUARY 27, 2023

Evusheld is not currently authorized for use

Thursday, Jan. 26, 2023, The U.S. Food and Drug Administration (FDA) announced a revision to the Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ciglavimab). **Evusheld is not currently authorized for emergency use in the U.S. until further notice by the FDA.**

Recent data from the Centers for Disease Control and Prevention (CDC) shows Evusheld is unlikely to be active against certain SARS-CoV-2 variants, which is why the FDA has revised the EUA. The most recent CDC data shows these variants are projected to be responsible for more than 90% of current infections in the U.S., which means Evusheld is not expected to provide protection against developing COVID-19 variants.

Health care providers should remain aware of the various authorized or approved COVID-19 treatments that are effective against currently circulating variants. Health care providers should assess what treatments are right for their patients.

It is recommended that facilities and providers keep any Evusheld that they have on hand in the event SARS-CoV-2 variants which are neutralized by Evusheld become more prevalent in the U.S. in the future.

Attached is further information. If you have any questions, please contact the ND Health and Human Services Operation Center at 701-328-0707.